Literature DB >> 21442346

The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy.

Sandra S Zaky1, Maryjo Lund, Kelly A May, Karen D Godette, Jonathan J Beitler, Leslie R Holmes, Ruth M O'Regan, Esther S Yu, David S Yu, Jerome C Landry.   

Abstract

PURPOSE: To evaluate disease failure patterns and overall survival (OS) of women with triple-negative (TN) breast cancer who underwent breast-conserving therapy (BCT) and to understand the relationship of TN tumors with other prognostic factors. PATIENTS AND METHODS: The Surveillance, Epidemiology, and End Results (SEER) registry identified 562 women diagnosed and/or treated with unilateral invasive breast cancer during 2003-2004 at three Emory hospitals. After medical record review, 193 eligible women, with all tumor types, received BCT. Primary endpoints (local, regional, and distant recurrences) and secondary endpoint (OS) were evaluated using chi-square tests and Cox proportional hazards models.
RESULTS: Of the 193 women, 33 (17.1%) had TN tumors and 160 (82.9%) had non-TN tumors. Patient characteristics were similar between the two tumor types; however, tumor grade and use of chemotherapy and hormones differed between the two groups. Median follow-up was 3.4 years; 22 patients had recurrence (12.2%), and 12 died (6.2%). Patients with TN tumors had higher local (12% versus 4% for non-TN) and distant recurrences (15% versus 4% for non-TN) rates (p = 0.01). On multivariate survival analyses, TN status [hazard ratio (HR) 1.8, 95% confidence interval (CI) 1.13-2.93] and African American (AA) race (HR 1.9, 95%CI 1.2-3.07) were independent predictors of inferior OS.
CONCLUSIONS: Patients with TN breast cancer showed significant increases in local and distant metastatic recurrence rates after BCT, and TN status and AA race were independent negative predictors of survival. For the future, identification of these high risk features may bring personalized medicine closer to reality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21442346     DOI: 10.1245/s10434-011-1669-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  15 in total

1.  Integrative analysis of lncRNAs and miRNAs with coding RNAs associated with ceRNA crosstalk network in triple negative breast cancer.

Authors:  Naijun Yuan; Guijuan Zhang; Yurong Wang; Fengjie Bie; Min Ma; Yi Ma; Xuefeng Jiang; Xiaoqian Hao
Journal:  Onco Targets Ther       Date:  2017-12-12       Impact factor: 4.147

Review 2.  Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis.

Authors:  Xin-Bin Pan; Song Qu; Yan-Ming Jiang; Xiao-Dong Zhu
Journal:  Breast Care (Basel)       Date:  2015-11-24       Impact factor: 2.860

3.  Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery.

Authors:  Gerd Fastner; Cornelia Hauser-Kronberger; Angelika Moder; Roland Reitsamer; Franz Zehentmayr; Peter Kopp; Christoph Fussl; Thorsten Fischer; Heinrich Deutschmann; Felix Sedlmayer
Journal:  Strahlenther Onkol       Date:  2015-09-24       Impact factor: 3.621

4.  Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.

Authors:  Teresa Cabezón; Irina Gromova; Pavel Gromov; Reza Serizawa; Vera Timmermans Wielenga; Niels Kroman; Julio E Celis; José M A Moreira
Journal:  Mol Cell Proteomics       Date:  2012-11-20       Impact factor: 5.911

5.  Radiation therapy following surgery for localized breast cancer: outcome prediction by classical prognostic factors and approximated genetic subtypes.

Authors:  Roberto Pacelli; Manuel Conson; Laura Cella; Raffaele Liuzzi; Giancarlo Troncone; Vincenzo Iorio; Raffaele Solla; Antonio Farella; Stefania Scala; Clorindo Pagliarulo; Marco Salvatore
Journal:  J Radiat Res       Date:  2012-09-26       Impact factor: 2.724

6.  Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.

Authors:  Pawel Domagala; Anna Jakubowska; Katarzyna Jaworska-Bieniek; Katarzyna Kaczmarek; Katarzyna Durda; Agnieszka Kurlapska; Cezary Cybulski; Jan Lubinski
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

7.  Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis.

Authors:  Katie R Hagen; Xiangbin Zeng; Mi-Young Lee; Shannon Tucker Kahn; Mary Kathryn Harrison Pitner; Sandra S Zaky; Yuan Liu; Ruth M O'Regan; Xingming Deng; Harold I Saavedra
Journal:  Cell Div       Date:  2013-07-25       Impact factor: 5.130

8.  Impact of radiation therapy on survival in patients with triple-negative breast cancer.

Authors:  Lauren T Steward; Feng Gao; Marie A Taylor; Julie A Margenthaler
Journal:  Oncol Lett       Date:  2013-11-22       Impact factor: 2.967

9.  Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy.

Authors:  Sanghwa Kim; Hyung Seok Park; Jee Ye Kim; Jegyu Ryu; Seho Park; Seung Il Kim
Journal:  Yonsei Med J       Date:  2016-09       Impact factor: 2.759

10.  RGD-conjugated mesoporous silica-encapsulated gold nanorods enhance the sensitization of triple-negative breast cancer to megavoltage radiation therapy.

Authors:  Ning Zhao; Zhangru Yang; Bingxin Li; Jin Meng; Zeliang Shi; Ping Li; Shen Fu
Journal:  Int J Nanomedicine       Date:  2016-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.